William S Jenkins1, Véronique L Roger2, Allan S Jaffe1, Susan A Weston3, Omar F AbouEzzeddine1, Ruoxiang Jiang3, Sheila M Manemann3, Maurice Enriquez-Sarano1. 1. Division of Cardiovascular Diseases in the Department of Internal Medicine, Mayo Clinic, Rochester, Minn. 2. Division of Cardiovascular Diseases in the Department of Internal Medicine, Mayo Clinic, Rochester, Minn; Department of Health Sciences Research, Mayo Clinic, Rochester, Minn. Electronic address: roger.veronique@mayo.edu. 3. Department of Health Sciences Research, Mayo Clinic, Rochester, Minn.
Abstract
BACKGROUND: Soluble ST2 (sST2) is a marker of cardiac mechanical strain hypothesized to adversely impact short-term prognosis after myocardial infarction. We examined the association of sST2 with longer-term outcomes after myocardial infarction in a geographically defined community. METHODS: Olmsted County, Minnesota residents who experienced an incident (first-ever) myocardial infarction between November 1, 2002 and December 31, 2012 were prospectively enrolled; sST2 levels were measured. Patients were followed for heart failure and death. RESULTS: We studied 1401 patients with incident myocardial infarction (mean age 67 years; 61% men; 79% non-ST-elevation myocardial infarction). Median sST2 (ng/mL) was 48.7 (25th-75th percentile 32.5-103.3). Soluble ST2 was elevated in 51% of patients. Higher values of sST2 were associated with increased age, female sex, and comorbidities. During 5 years of follow-up, 388 persons died and 360 developed heart failure. After adjustment for age, sex, comorbidities, Killip class, and troponin T, the hazard ratios for death were 1.73 (95% confidence interval [CI], 1.22-2.45) and 3.57 (95% CI, 2.57-4.96) for sST2 tertiles 2 and 3, respectively (Ptrend <.001). For heart failure, the hazard ratios were 1.67 (95% CI, 1.18-2.37) and 2.88 (95% CI, 2.05-4.05), respectively (Ptrend <.001). Results were similar among 30-day survivors. CONCLUSIONS: In the community, sST2 elevation is present in half of myocardial infarctions. Higher values of sST2 are associated with a large excess risk of death and heart failure independently of other prognostic indicators. Measurement of sST2 should be considered for risk stratification after myocardial infarction.
BACKGROUND: Soluble ST2 (sST2) is a marker of cardiac mechanical strain hypothesized to adversely impact short-term prognosis after myocardial infarction. We examined the association of sST2 with longer-term outcomes after myocardial infarction in a geographically defined community. METHODS: Olmsted County, Minnesota residents who experienced an incident (first-ever) myocardial infarction between November 1, 2002 and December 31, 2012 were prospectively enrolled; sST2 levels were measured. Patients were followed for heart failure and death. RESULTS: We studied 1401 patients with incident myocardial infarction (mean age 67 years; 61% men; 79% non-ST-elevation myocardial infarction). Median sST2 (ng/mL) was 48.7 (25th-75th percentile 32.5-103.3). Soluble ST2 was elevated in 51% of patients. Higher values of sST2 were associated with increased age, female sex, and comorbidities. During 5 years of follow-up, 388 persons died and 360 developed heart failure. After adjustment for age, sex, comorbidities, Killip class, and troponin T, the hazard ratios for death were 1.73 (95% confidence interval [CI], 1.22-2.45) and 3.57 (95% CI, 2.57-4.96) for sST2 tertiles 2 and 3, respectively (Ptrend <.001). For heart failure, the hazard ratios were 1.67 (95% CI, 1.18-2.37) and 2.88 (95% CI, 2.05-4.05), respectively (Ptrend <.001). Results were similar among 30-day survivors. CONCLUSIONS: In the community, sST2 elevation is present in half of myocardial infarctions. Higher values of sST2 are associated with a large excess risk of death and heart failure independently of other prognostic indicators. Measurement of sST2 should be considered for risk stratification after myocardial infarction.
Authors: Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Sheila M Manemann; Alanna M Chamberlain; Ruoxiang Jiang; Véronique L Roger Journal: JAMA Cardiol Date: 2016-05-01 Impact factor: 14.676
Authors: Véronique L Roger; Susan A Weston; Yariv Gerber; Jill M Killian; Shannon M Dunlay; Allan S Jaffe; Malcolm R Bell; Jan Kors; Barbara P Yawn; Steven J Jacobsen Journal: Circulation Date: 2010-02-08 Impact factor: 29.690
Authors: Domingo A Pascual-Figal; Sergio Manzano-Fernández; Miguel Boronat; Teresa Casas; Iris P Garrido; Juan C Bonaque; Francisco Pastor-Perez; Mariano Valdés; James L Januzzi Journal: Eur J Heart Fail Date: 2011-05-06 Impact factor: 15.534
Authors: Robert W Yeh; Stephen Sidney; Malini Chandra; Michael Sorel; Joseph V Selby; Alan S Go Journal: N Engl J Med Date: 2010-06-10 Impact factor: 91.245
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Véronique L Roger; Steven J Jacobsen; Susan A Weston; Tauqir Y Goraya; Jill Killian; Guy S Reeder; Thomas E Kottke; Barbara P Yawn; Robert L Frye Journal: Ann Intern Med Date: 2002-03-05 Impact factor: 25.391
Authors: Jessica C Garbern; Jason Williams; Amy C Kristl; Alyyah Malick; Inbal Rachmin; Benjamin Gaeta; Nafis Ahmed; Ana Vujic; Peter Libby; Richard T Lee Journal: J Mol Cell Cardiol Date: 2019-02-11 Impact factor: 5.000
Authors: Rabea Asleh; Maurice Enriquez-Sarano; Allan S Jaffe; Sheila M Manemann; Susan A Weston; Ruoxiang Jiang; Véronique L Roger Journal: J Am Coll Cardiol Date: 2019-05-14 Impact factor: 24.094
Authors: Mustafa Umut Somuncu; Tunahan Akgun; Mustafa Ozan Cakır; Ferit Akgul; Nail Guven Serbest; Huseyin Karakurt; Murat Can; Ali Riza Demir Journal: J Atheroscler Thromb Date: 2019-04-18 Impact factor: 4.928
Authors: Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Allan S Jaffe; Sheila M Manemann; Ruoxiang Jiang; Véronique L Roger Journal: J Am Heart Assoc Date: 2017-10-20 Impact factor: 5.501
Authors: Laurie W Geenen; Vivan J M Baggen; Annemien E van den Bosch; Jannet A Eindhoven; Judith A A E Cuypers; Maarten Witsenburg; Eric Boersma; Jolien W Roos-Hesselink Journal: Heart Date: 2019-01-30 Impact factor: 5.994